Abstract
Hemophilia is a rare bleeding disorder, for which treatments are still being developing and several new agents are providing better quality of life for patents. National evidence- and/or practice-based guidelines have been published by JSTH. Recommendations offered for the hemostatic management of hemophilia have assisted healthcare providers in initiating general hemophilia care. This article first reviews the two national guidelines for patients with/without inhibitor treatments. Then, future perspectives on progress in current treatment as well as the newer agents are summarized. Treatment options anticipated to be available in the near future are proposed for all caregivers in Japan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
